Aurobindo to buy Actavis' loss-making West Europe units

Deal expands Aurobindo's front-end operations into five segments with 1,200 products, additional pipeline of 200 products

BS Reporter Hyderabad
Last Updated : Jan 18 2014 | 11:09 PM IST
Hyderabad-based drug maker Aurobindo Pharma on Saturday said it would buy Irish drug maker Actavis’ loss-making generics operations in seven western European countries.  

The company said the total consideration for the acquisition was expected to be Euro 30 million and would depend upon the cash and net working capital position when the deal is closed. Aurobindo plans to fund the acquisition through internal accruals. The transaction is conditional on antitrust approvals and completion of employee consultation processes. Aurobindo expects to buy personnel, commercial infrastructure, products, marketing authorisations and dossier licence rights in France, Italy, Spain, Portugal, Belgium, Germany and the Netherlands.

Actavis and Aurobindo will be entering into a long-term commercial and supply arrangement to support the growth plans of these operations. The acquisition expands Aurobindo’s front-end operations into five segments —generics, prescription products, over-the-counter products, hospital products and generics tenders — with about 1,200 products and 200 more in the works.

The management estimates net sales for the businesses acquired would be Euro 320 million in 2013, growing at 10 per cent year-on-year. Aurobindo expects these loss-making businesses to turn profitable in combination with its vertically integrated platform. Since 2006, Aurobindo has been expanding its reach in Europe, with operations in the UK, Spain and Germany. The acquisition will help Aurobindo achieve critical mass in western Europe, quickening entry into the top 10 league in some key markets.

“This transaction will complement our strategy of pursuing organic growth along with value-creating acquisitions within our served markets and adding complementary growth platforms to provide scale and revenue diversity,” senior vice-president of European operations, V Muralidharan, said.

Jefferies International Ltd was the financial advisor and Herbert Smith Freehills the legal counsel to Aurobindo. Rothschild and Latham & Watkins were the financial advisor and legal counsel to Actavis, respectively.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 18 2014 | 10:39 PM IST

Next Story